mCRPC Treatment

Delay Chemotherapy in Hormone Sensitive Metastatic Prostate Cancer

Details
Delay Chemotherapy in Hormone Sensitive Metastatic Prostate Cancer State of the Art presentation by Michael Cookson, MD. with interview by E. David Crawford, MD. Michael Shawn Cookson, M.D., M.M.H.C., is Professor and Chairman of the Department of Urology at the University of Oklahoma College of Medicine. He holds the Donald D. Albers Endowed Chair in Urology. A graduate of the University of Oklah...

Detection of Metastatic Disease: Review of the RADAR Group Recommendations

Details
Phil Koo, MD. reviews the detection of metastatic catration-resistant prostate cancer disease in a Review of the RADAR Group Recommendations

IMAAGEN Trial Update: Effect of Abiraterone Acetate and Low Dose Prednisone on PSA in Patients with Non-Metastatic Castration-Resistant Prostate Cancer

Details
Charles Ryan presents an update to the IMAAGEN Trial which includes the percentage of patients with event-free rates for PSA progression at 12, 18, and 24 months and radiographic evidence of disease progression with non-metastatic castration-resistant prostate cancer when taking abiraterone acetate and low dose predisone. Biography Charles J. Ryan, MD is Professor of Clinical Medicine and Urology...

Prostate Cancer: The Year in Review

Details
Fred Saad, MD FRCS, presents the Year in Review for Prostate Cancer 2015 as presented at the ASCO GU 2016. Fred Saad MD FRCS, is Professor and Chief of Urology and Director of GU Oncology at the University of Montreal Hospital Centers (CHUM). He holds the U of M Endowed Chair in Prostate Cancer and is Director of the molecular oncology research lab in Prostate Cancer. He has recently been appointe...

A Century of Progress in Urologic Cancers 1915-2015 - MSKCC

Details
Peter Scardino, Chair, Department of Surgery; David H. Koch Chair, shares the illustrious history of urologic oncology at MSKCC and discusses the upcoming Memorial Sloan Kettering Centennial Conference, Modern Management of Urologic Cancers: A Multidisciplinary Approach. Thomas Keane interviews Peter Scardino about the contrubtions and accomplishments to the field of urologic oncology at Memorial...

Abiraterone in Elderly Chemotherapy-Naive Patients with mCRPC

Details
Charles J. Ryan, MD. - Journal Club: Efficacy and Safety of Abiraterone Acetate in Elderly Chemotherapy-Naive Patients with Metastatic Castration-Resistant Prostate Cancer Article Abstract: Purpose: Metastatic castration-resistant prostate cancer primarily affects elderly men. In this post hoc analysis we investigated the safety and efficacy of abiraterone acetate in elderly (≥75 years) and younge...

Practical Considerations in the Use of Novel Hormone Agents in the Post-ADT Setting

Details
Practical Considerations in the Use of Novel Hormone Agents in the mCRPC Patient Dr. Ryan delivers a concise presentation on clinical considerations in selecting treatment for the mCRPC patient. He walks though discussions on the Right Patient - the Right Therapy - Right Time - Right Patient. He also presents his objectives in determining treatment after ADT fails on its own. He looks to Preserve...